Search

Displaying results 5301 - 5310 of 10000 in total
  1. Drug

    Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15680
    ApprovedInvestigational

  2. Drug

    Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15681
    ApprovedInvestigational

  3. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol. … It has since been demonstrated that the agent possesses activity against amoebas and yaws.

    Categories: Antiparasitic Products, Insecticides and Repellents
  4. Drug

    Picric acid

    go.drugbank.com/drugs/DB03651
    Approved

    Used as antiseptic, astringent, and stimulant for epitheliazation.

    Categories: Indicators and Reagents
  5. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

    Categories: Dopa and Dopa Derivatives, foslevodopa and decarboxylase inhibitor
  6. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR-16 is under investigation by NeuroSearch. … ’s disease, Parkinson’s disease and schizophrenia respectively.

  7. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

  8. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

  9. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. … In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma.

  10. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. … Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion.